Outcome of Nomination and Remuneration Committee Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Nomination and Remuneration Committee of the Company, at its meeting held on March 31, 2015 has cancelled 46,400 stock options pursuant to ESOS 2003.31-03-2015